Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.36 |
| ▸ | M6PR | P20645 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | AHCY | P23526 | 2/20 | 0.30 |
| ▸ | CA1 | P00915 | 5/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13498556 | 1.00 | CA2 (0.38) | CA2CA9CA12FUCA1M6PR | |
| SCHEMBL16327272 | 1.00 | CA2 (0.38) | CA2CA9CA12FUCA1M6PR | |
| SCHEMBL13887631 | 1.00 | CA2 (0.38) | CA2CA9CA12FUCA1M6PR | |
| SCHEMBL21782823 | 0.98 | CA9 (0.35) | CA2CA9CA12FUCA1M6PR | |
| SCHEMBL24599501 | 0.84 | CA9 (0.33) | CA2CA9CA12FUCA1 | |
| SCHEMBL26824644 | 0.76 | FUCA1 (0.36) | CA2CA9CA12FUCA1SMN1; SMN2 | |
| SCHEMBL12900024 | 0.76 | M6PR (0.33) | CA2CA9CA12M6PR | |
| SCHEMBL4270346 | 0.75 | AHCY (0.32) | AHCY | |
| SCHEMBL3491867 | 0.75 | AHCY (0.32) | AHCY | |
| SCHEMBL8616449 | 0.75 | AHCY (0.32) | AHCY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140274903-A1 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | NOVO NORDISK HEALTHCARE AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | VIP, PTMS, PDGFA | CA2 4642/4885CA9 4490/4885CA12 3043/4885 |
| US-20140274903-A1 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | GALE, GALNT2, GALNT1 | CA2 4039/4885CA9 3627/4885CA12 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.